CHARLIE Mullins, Britain’s richest plumber, has revealed why he made the move to Marbella and where he has set his sights on building a new home.
entrepreneurship
LA Knight spoke to Brad Gilmore on how he knew within his first year that he could achieve greatness in the wrestling business.
Former President Donald Trump again poured cold water on the idea of a second debate with Vice President Kamala Harris, telling supporters at a North Carolina rally Saturday that it's "just too late, voting has already started." This comes after Harris accepted an invitation from CNN for a possible second debate in October. Nikole Killion has the latest.
All Elite Wrestling commentator Jim Ross weighs in on all of the surprise appearances JBL has made in recent months.
Get hyped for the return of Nong-O Gaiyanghadao at ONE Lumpinee 1 against Alaverdi Ramazanov by seeing how he took care of business against Hiroaki Suzuki.
The City of Tempe claims EasyrideZ LLC’s permission to rent scooters in parks was a two year misunderstanding.
Cater Worth looks at the signs that Pfizer is starting to reverse the trend.
Tom E. Curran and Phil Perry discuss why the Patriots should continue to roll with Jacoby Brissett over Drake Maye as their starting QB despite the offense’s struggles.
The Patriots head coach made a surprising decision on who will start for New England moving forward.
The days may be getting shorter, but Illinois’ fall colors are just starting to come alive. Northern Illinois will see peak foliage by the second week of…
Weight loss drugs are exploding in popularity, with 1 in 8 Americans saying they have tried medications like Ozempic and Wegovy to tackle everything from diabetes to weight loss, among other conditions. As demand rises, many people are turning to copycat alternatives, or compounded versions, of the drugs. CBS News Confirmed looked into the marketplace for these alternatives and found plenty of gray area, with little oversight or protection for consumers.
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the meantime, a market for cheaper, compounded drugs thrives.